Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 891 across all filing types
Latest filing 2025-04-01 Proxy Solicitation & In…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' for Swedish Orphan Biovitrum AB. It contains the agenda, proposals for board elections, remuneration policies, and instructions for shareholder participation (in-person or postal voting). This document is a classic proxy statement/notice of meeting sent to shareholders to solicit votes and provide information for the upcoming AGM.
2025-04-01 English
Annual Report (ESEF) 2024
Annual Report (ESEF) Classification · 100% confidence FY 2024
2025-03-31 Swedish
Earnings Release 2024
Earnings Release Classification · 99% confidence The document is titled "Bokslutskommuniké för 2024" (Year-end report/Financial Statement Release for 2024) and contains detailed financial figures for the Fourth Quarter (Kv4 2024) and the Full Year (Helår 2024). It includes key performance indicators like operating revenue, EBITA margin, EPS, and outlook for 2025. This structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR), but since it covers the full year ('Bokslutskommuniké') and provides comprehensive financial tables, it leans towards a full financial report, though it is presented as a 'kommuniké' (release/communication). However, the content is a high-level summary of the full year's results, including management commentary and key highlights, which strongly aligns with the definition of an Earnings Release (ER) – the initial announcement of periodical financial results (key highlights only). While it covers the full year, the format is that of a press release summarizing the results rather than the full, audited 10-K document. Given the Swedish context and the term 'Bokslutskommuniké', this is the primary announcement of the annual results. If a more comprehensive, regulatory filing (like a 10-K equivalent) existed, this would be the precursor. Therefore, 'ER' (Earnings Release) is the most appropriate classification for this type of results announcement summary. Q4 2024
2025-02-05 Swedish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document text explicitly states it is a "Q4 and FY 2024 report" and provides detailed financial results for the Fourth Quarter 2024 and the Full Year 2024, including revenue, EBITA margins, EPS, and outlook for 2025. This content structure—comprehensive financial performance review for a full fiscal year, often accompanied by a CEO statement—is characteristic of an Annual Report (10-K) or a very detailed Interim/Quarterly Report (IR). Since it covers the full fiscal year ('FY 2024') and contains extensive financial tables and management commentary, it strongly aligns with the scope of a comprehensive annual filing. Although the text does not explicitly mention '10-K', the depth and scope covering the entire year make it the most appropriate classification among the provided options, as it is much more detailed than a simple Earnings Release (ER) or a short Fund Factsheet (FS). Given the comprehensive nature covering the full year, it is classified as an Annual Report (10-K), assuming this document is the primary filing containing these results, rather than just a press release announcing them (which would be ER). The length (136,064 chars) also supports it being a full report. FY 2024
2025-02-05 English
Sobis intäkter för helåret 2024 högre än tidigare uppskattningar
Earnings Release Classification · 100% confidence The document is a press release from Sobi announcing preliminary financial results (revenue and EBITA margin) for the full year 2024, which exceeded previous guidance. It provides key highlights of the performance drivers but explicitly states that the full report for the fourth quarter and full year 2024 will be published on February 5, 2025. Since this is an initial announcement of financial highlights rather than the full report itself, it falls under the Earnings Release (ER) category. FY 2024
2025-01-10 Swedish
Sobi's full year 2024 revenue higher than previous estimate
Earnings Release Classification · 100% confidence The document is a press release issued by Sobi on January 10, 2025, providing preliminary financial highlights (revenue growth and EBITA margin) for the full year 2024 ahead of the official report release. It explicitly states that the full report will be announced on February 5, 2025. Since this is an initial announcement of financial results (key highlights only) and not the full report itself, it falls under the Earnings Release (ER) category. FY 2024
2025-01-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.